BRCA2 and cancer: The seminal findings that inhibition of PARP1/2 in BRCA1/BRCA2 mutated cancer cells selectively kills the cancer cells, but leaves the wild type BRCA1/BRCA2 cells intact, helped define a new epoch in personalised medicine that is already transforming patients’ lives.